Company profile
Carisma Therapeutics, Inc.
OTC: CARM · Healthcare · Biotechnology
#546 of 1,418 Healthcare companies by revenue72nd-percentile growth
EA Score
——FH —DQ 69GM —SS 42
v0.1 · 25/100 weight · pillars only
↑ disclosure history, revenue growth (YoY) · ↓ market scale, return on assets
Methodology →Revenue TTM
$52.6M
Rev growth YoY (TTM)
+159.7%
Net income (FY)
-$60.5M
Employees
46
as of 2026-08-27
Market cap
$54.4k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$19.6M$19.6M2024
Net income-$60.5M-$60.5M2024
Operating income-$62.2M-$62.2M2024
Total assets$30.5M$30.5M2024
Liabilities$58.4M$58.4M2024
Equity-$27.9M-$27.9M2024
Revenue trend
FY2019 – FY2024 · USD
FY19
FY19
FY19
FY20
FY21
FY23
FY23
FY24
Revenue by segment
Filed disclosures · FY2024
By product
Milestones100%
By geography
Not disclosed.
The read
What is Carisma Therapeutics, Inc.’s revenue?
Carisma Therapeutics, Inc. booked $19.6M in FY2024 revenue, growing 32% year over year — faster than most Healthcare companies we track, at a -308.6% net margin.
Peers · Healthcare
Nutrition Management Services Company——Immix Biopharma, Inc.49DSpectral AI, Inc.39DSonoma Pharmaceuticals, Inc.60CAvem Health Partners, Inc.——cbdMD, Inc.49DNeighbors
Philadelphia →Key facts
CEOCraig R. Jalbert
SectorHealthcare
IndustryBiotechnology
HeadquartersPhiladelphia, PA
ExchangeOTC: CARM
Employees46
IPO date2014-02-06
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.